Loading...
XNASABVX
Market cap466mUSD
Dec 24, Last price  
7.60USD
1D
3.40%
1Q
-31.90%
IPO
-8.43%
Name

Abivax SA

Chart & Performance

D1W1MN
XNAS:ABVX chart
P/E
—
P/S
100.17
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
33.36%
Rev. gr., 5y
203.31%
Revenues
5m
+0.83%
74,87267,13442,000127,00010,00018,00023,00063,00037,0004,583,0004,621,000
Net income
-148m
L+111.52%
-5,893,547-8,099,362-15,954,000-14,308,000-11,223,000-15,823,000-30,634,000-37,551,000-41,357,000-69,846,000-147,740,000
CFO
-100m
L+257.32%
-3,305,008-14,904,000-15,608,000-8,449,000-14,603,000-27,473,000-29,823,000-45,657,000-27,989,000-100,009,000
Earnings
Mar 31, 2025

Profile

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
URL
https://www.abivax.com/
IPO date
Jun 26, 2015
Employees
22
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
4,621
0.83%
4,583
12,286.49%
37
-41.27%
Cost of revenue
132,704
98,441
92,327
Unusual Expense (Income)
NOPBT
(128,083)
(93,858)
(92,290)
NOPBT Margin
Operating Taxes
(4,493)
(4,476)
(4,204)
Tax Rate
NOPAT
(123,590)
(89,382)
(88,086)
Net income
(147,740)
111.52%
(69,846)
68.89%
(41,357)
10.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
353,387
28,592
65,466
BB yield
-83.56%
-20.75%
-13.69%
Debt
Debt current
10,607
9,491
7
Long-term debt
45,396
37,414
53,658
Deferred revenue
Other long-term liabilities
16,153
39
98
Net debt
(217,285)
19,884
(7,250)
Cash flow
Cash from operating activities
(100,009)
(27,989)
(45,657)
CAPEX
(266)
(43)
(1,642)
Cash from investing activities
(10,495)
(513)
(1,456)
Cash from financing activities
340,569
48,033
78,512
FCF
(121,449)
(92,307)
(88,079)
Balance
Cash
260,992
26,950
60,701
Long term investments
12,296
71
214
Excess cash
273,057
26,792
60,913
Stockholders' equity
(282,208)
(148,248)
(78,458)
Invested Capital
549,834
202,968
167,532
ROIC
ROCE
EV
Common stock shares outstanding
43,066
22,301
16,755
Price
9.82
58.90%
6.18
-78.35%
28.55
-17.01%
Market cap
422,908
206.85%
137,821
-71.19%
478,368
-2.81%
EV
205,623
157,705
471,118
EBITDA
(127,376)
(93,549)
(92,134)
EV/EBITDA
Interest
15,825
3,696
3,151
Interest/NOPBT